Improving immunotherapy through immune checkpoint assays, CAR-T target display, and effector function optimization

Cancer and autoimmune disease lead to illness by damaging and evading a patients natural defenses. Immunotherapy methods are designed to reclaim and bolster the immune system to treat disease. This requires both highly specific binding of therapeutic agents to target molecules and optimizing techniq...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of immunology (1950) 2019-05, Vol.202 (1_Supplement), p.71-71.19
Main Authors: Edgcomb, Stephen, Zhu, Jie, Tao, Zhihua, Hsu, Matthew, Kimbara, Michelle, Oberle, Suzan, Zhu, Henry
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer and autoimmune disease lead to illness by damaging and evading a patients natural defenses. Immunotherapy methods are designed to reclaim and bolster the immune system to treat disease. This requires both highly specific binding of therapeutic agents to target molecules and optimizing techniques to harness the effector functions of the immune system. We describe methods for both these requirements. These include cell based systems for improving attachment to targets by assaying binding of therapeutic antibodies to immune checkpoint receptors and displaying molecular targets to CAR- T cells. They also include assays to improve immune effector functions such as Antibody-dependent cell-mediated cytotoxicity (ADCC) through cell based assays of IgG Fc binding to FCgRs.
ISSN:0022-1767
1550-6606
DOI:10.4049/jimmunol.202.Supp.71.19